Eli Lilly & Co. won a U.K. patent lawsuit against a Johnson & Johnson unit over a potential treatment for Alzheimer’s disease.
A patent held by J&J’s Janssen Alzheimer Immunotherapy Research & Development unit isn’t valid, Judge Richard Arnold said in a ruling in London today. Both companies are developing treatments targeting the build-up of plaque in patients’ brains that’s linked to the condition.
Companies developing the first treatments for Alzheimer’s are competing for what might be a $20 billion market, according to a report last year by Deutsche Bank AG analysts.
“We are disappointed by the outcome of this case, and we are considering our options,” Greg Panico, a U.S. spokesman for Janssen, said in an e-mail.
Lilly is “focused on discovering and developing innovative medicines to meet the needs of patients,” the company said in an e-mailed statement. “This decision by the court supports that effort.”
The case is Eli Lilly and Co. v. Janssen Alzheimer Immunotherapy, High Court of Justice, Chancery Division, HC11C03400